Hyponatremia: Complete Clinical Reference

1. CLASSIFICATION / TYPES

By Serum Osmolality

By Volume Status (Hypotonic Hyponatremia)

• GI losses: vomiting, diarrhea, fistulas
• Skin losses: burns, sweating
• Third spacing: bowel obstruction, pancreatitis, rhabdomyolysis
• Renal causes: thiazide diuretics (most common drug cause), mineralocorticoid deficiency (Addison's), salt-wasting nephropathies, osmotic diuresis, renal tubular acidosis
• Urine Na: <20 mEq/L (extrarenal) or >20 mEq/L (renal)

• SIADH (most common cause of euvolemic hyponatremia)
• Drugs causing SIADH: diuretics, carbamazepine, SSRIs, cyclophosphamide, vincristine, cisplatin, opioids, barbiturates, chlorpropamide, scopolamine
• Psychogenic polydipsia / beer potomania
• Hypothyroidism
• Adrenal insufficiency
• MDMA (ecstasy) use
• Urine Na: >20 mEq/L (except polydipsia: <20 mEq/L)

• Congestive heart failure
• Liver cirrhosis / hepatic failure
• Nephrotic syndrome / chronic renal failure
• Urine Na: <20 mEq/L (CHF, cirrhosis - renal hypoperfusion) or >20 mEq/L (renal failure)

By Duration

• Acute: <48 hours (brain has not adapted - high risk of cerebral edema)
• Chronic: >48 hours (brain adaptation via loss of organic osmolytes - high risk of osmotic demyelination if corrected too fast)

By Severity

• Mild: 130-134 mEq/L
• Moderate: 125-129 mEq/L
• Severe: <125 mEq/L (with or without symptoms)
• Profound/Critical: <115-120 mEq/L

2. CLINICAL FEATURES, SIGNS & SYMPTOMS

Mild-Moderate (Na 125-134 mEq/L)

• Anorexia, nausea, vomiting
• Generalized weakness, fatigue, malaise
• Headache
• Muscle cramps
• Cognitive slowing, difficulty concentrating

Moderate-Severe (Na 120-125 mEq/L)

• Worsening confusion, disorientation
• Gait disturbance, increased fall risk (especially in elderly - doubled risk with large-bone fractures)
• Lethargy, drowsiness

Severe / Acute (<120 mEq/L or rapid drop)

• Severe confusion, stupor
• Seizures (often refractory)
• Coma
• Respiratory arrest
• Brainstem herniation (life-threatening)

Volume Status Clues on Examination

• Hypovolemic: Reduced skin turgor, prolonged capillary refill, dry mucous membranes, orthostatic hypotension/tachycardia, sunken eyes
• Hypervolemic: Jugular venous distension, peripheral edema, ascites, pulmonary crackles, S3 gallop
• Euvolemic (SIADH): No edema, normal skin turgor, no signs of dehydration or volume overload

3. DIAGNOSTIC APPROACH

Step 1 - Confirm True Hyponatremia

• Check serum osmolality to exclude pseudo- and hypertonic hyponatremia
• In hyperglycemia: corrected Na = measured Na + 1.6 × [(glucose - 100)/100]

Step 2 - Assess Volume Status

Step 3 - Urine Studies (Key Tests)

Step 4 - Additional Labs

• Serum potassium (low in Bartter, thiazides, vomiting; high in adrenal insufficiency)
• Serum urea / creatinine / uric acid (low uric acid in SIADH)
• Thyroid function (rule out hypothyroidism)
• Morning cortisol (rule out adrenal insufficiency - critical before diagnosing SIADH)
• LFTs, BNP/NT-proBNP (heart failure workup)
• Chest X-ray (pulmonary causes of SIADH: TB, sarcoid, malignancy)

SIADH Diagnostic Criteria (Bartter-Schwartz)

1. Serum hypo-osmolality (<275 mOsm/kg)
2. Inappropriately concentrated urine (>100 mOsm/kg)
3. Urine Na >20-30 mEq/L with normal salt intake
4. Clinical euvolemia
5. Normal thyroid, adrenal function
6. No recent diuretic use

4. MANAGEMENT PROTOCOLS

A. Emergency Management - Severe Symptomatic Hyponatremia (Seizures, Coma, Herniation)

1. Give 150 mL of 3% hypertonic saline IV over 20 minutes
2. Check sodium after 20 minutes
3. If Na rose by <5 mEq/L and symptoms persist: repeat 150 mL 3% NaCl over 20 minutes (can repeat once more if needed, maximum 3 infusions)
4. Once 5 mEq/L rise achieved or symptoms improve: stop bolus therapy
5. Switch to minimum maintenance fluid (0.9% NaCl)
6. Total correction must not exceed 10 mEq/L in 24 hours and 8 mEq/L per subsequent 24-hour period

B. Hypovolemic Hyponatremia

• Isotonic saline (0.9% NaCl) is the treatment of choice
• Restoring volume suppresses ADH, which triggers free water excretion - this can cause rapid auto-correction
• Monitor Na closely every 2-4 hours to avoid overcorrection
• Remove the underlying cause (stop offending diuretics, treat GI losses)

C. Euvolemic Hyponatremia (SIADH)

1. Treat the underlying cause (stop causative drug, treat infection/malignancy, etc.)
2. Fluid restriction - first-line for mild/moderate:
   • Restrict to 500 mL less than urine output (typically 800-1000 mL/day total)
   • Only effective if urine is sufficiently concentrated (Uosm/Posm ratio <1 predicts good response)
   • Compliance is notoriously poor
3. Salt tablets + loop diuretics (furosemide 20-40 mg + salt tablets): increases solute load and prevents renal water retention
4. Oral urea (15-30 g/day in juice): acts as osmotic diuretic, promotes free water excretion
   • A 2025 meta-analysis (PMID: 39362395) confirms urea significantly raises serum Na (mean increase +9.08 mEq/L, 95% CI 7.64-10.52) and is comparable to vaptans and fluid restriction, with only minor adverse effects (palatability being the main issue). Especially effective in severe SIADH.
5. Vaptans (V2-receptor antagonists):
   • Tolvaptan (oral, 15-60 mg/day): blocks V2 receptors in collecting duct, promotes aquaresis (electrolyte-free water excretion)
   • Conivaptan (IV, 20-40 mg/day): dual V1a/V2 blocker - for inpatient use
   • Avoid in hypovolemic hyponatremia (dangerous)
   • Risk of liver toxicity (tolvaptan is contraindicated long-term - FDA black box warning for polycystic kidney disease doses; caution in liver disease)
   • Risk of overcorrection - must be started in-hospital with close monitoring
   • Start only if serum Na <125 mEq/L or symptomatic; do not initiate if Na rises rapidly on its own
6. Demeclocycline (300-600 mg twice daily): causes nephrogenic DI, rarely used now due to nephrotoxicity risk
7. Lithium: rarely used for SIADH (toxicity profile)

D. Hypervolemic Hyponatremia (Heart Failure, Cirrhosis, Nephrotic Syndrome)

• Fluid restriction (1.0-1.5 L/day) - mainstay
• Sodium restriction (2 g/day)
• Treat the underlying condition aggressively:
  • CHF: optimize diuresis (furosemide, spironolactone), ACE inhibitors, beta-blockers
  • Cirrhosis: diuretics (spironolactone + furosemide), avoid tolvaptan (hepatotoxicity risk - not FDA approved for cirrhosis); short-term tolvaptan may be used only as bridge to liver transplantation (Goldman-Cecil: 15 mg/day, increased to 30-60 mg/day if needed - PMID 41114681 AGA 2025 guidelines concur)
  • Nephrotic syndrome: treat underlying glomerular disease
• Avoid hypertonic saline in most hypervolemic states (worsens fluid overload)
• TIPS (transjugular intrahepatic portosystemic shunt): For refractory hyponatremia in cirrhosis (AGA 2025 BPA #7)
• Intravenous albumin: for cirrhosis with severe/symptomatic hyponatremia (AGA 2025 BPA #10)

E. Chronic Asymptomatic Hyponatremia

• Correction rate: no more than 6-8 mEq/L per 24 hours
• Treat underlying cause
• Fluid restriction for SIADH
• Follow serial sodium checks every 4-6 hours initially

5. SODIUM CORRECTION TARGETS

Standard Targets (Current Guidelines)

Sodium Correction Formula (Adrogue-Madias)

ΔNa = (Infusate Na - Serum Na) / (Total body water + 1)

• Total body water = 0.6 × weight (kg) for men; 0.5 × weight (kg) for women; 0.45 × weight (kg) for elderly women
• 3% NaCl Na content = 513 mEq/L
• 0.9% NaCl Na content = 154 mEq/L

IMPORTANT 2025 Evidence Update on Correction Rates

Slow correction (< 8 mEq/L/24 hrs) and very slow correction (< 4-6 mEq/L/24 hrs) were associated with significantly HIGHER mortality compared to rapid correction (≥ 8-10 mEq/L/24 hrs).

• Rapid correction: 32 fewer in-hospital deaths per 1000 treated vs. slow, and 221 fewer deaths vs. very slow correction
• Rapid correction: 61-134 fewer deaths per 1000 at 30 days
• Rapid correction: shorter hospital stay by 1.2-3.1 days
• Rapid correction was NOT associated with significantly increased ODS risk

Overcorrection Management (If Na rises too fast)

• Administer free water (5% dextrose in water, 3-5 mL/kg IV)
• Desmopressin (DDAVP) 1-2 mcg IV/SC every 6-8 hours - "clamps" the kidneys, prevents further free water excretion
• Goal: bring Na back down to within safe correction range
• Relowering is most effective within 12-24 hours of overcorrection

6. COMPLICATIONS

Complications of Hyponatremia Itself

• Cerebral edema - the primary life-threatening complication of acute hyponatremia
• Transtentorial herniation, brainstem compression
• Seizures (often refractory to standard antiepileptics alone - need sodium correction)
• Non-cardiogenic pulmonary edema
• Respiratory failure / arrest
• Increased fall risk and fractures (especially hip fractures in elderly)
• Cognitive impairment (even with mild chronic hyponatremia)
• Poor wound healing, increased infection risk
• In cancer: 3-5x increased 90-day mortality; doubled hospital LOS

Osmotic Demyelination Syndrome (ODS) - Complication of Treatment

• Previously called Central Pontine Myelinolysis (CPM); can also be Extrapontine Myelinolysis
• Occurs when serum Na is corrected too rapidly in chronic hyponatremia
• Mechanism: after brain loses organic osmolytes to adapt to hyponatremia, rapid re-rise in plasma osmolality causes sudden fluid efflux from neurons → demyelination
• High-risk groups: Alcoholism/malnutrition, hypokalemia, liver transplant recipients, severe malnutrition, burn patients, women on thiazides
• Clinical presentation (delayed - 2-6 days after overcorrection):
  • Dysarthria, dysphagia
  • Paraparesis, quadriparesis
  • "Locked-in" syndrome (severe pontine involvement)
  • Behavioral/cognitive changes (extrapontine)
  • Coma
• Diagnosis: MRI (T2/FLAIR hyperintensity in pons or basal ganglia - may not appear for 1-2 weeks)
• Treatment: Supportive; DDAVP + free water to re-lower if caught early; no proven specific therapy
• Prevention: Strict adherence to correction rate targets; identify high-risk patients; liberal use of DDAVP prophylaxis

Non-hyponatremia-associated ODS (2026 Update)

7. SPECIAL POPULATIONS

Beer Potomania / Tea-and-Toast Syndrome

• Extremely low solute intake with high water intake
• Urine Osm may be near minimum (50 mOsm/kg), severely limiting free water excretion capacity
• A 2025 systematic review (PMID 40573123) confirms the clinical phenotype and underscores the need for solute repletion, not just fluid restriction

Pediatric Hyponatremia

• Main causes: hypotonic formula, excessive water enemas, GI losses
• High-risk: children post-op (ADH surge), young women, endurance athletes
• Treat cautiously - brain more susceptible to both edema and ODS
• Isotonic maintenance fluids are now preferred over hypotonic in hospitalized children (2024 meta-analysis PMID 37365423)

Elderly

• Risk doubles with large-bone fractures
• Often on thiazides (most common drug cause)
• Chronic, asymptomatic hyponatremia associated with significant cognitive impairment and fall risk

Cirrhosis

• 2025 AGA Practice Guideline (PMID 41114681): fluid and sodium restriction first-line; avoid tolvaptan except as bridge to transplant; consider TIPS for refractory cases; multidisciplinary approach required

8. RECENT ADVANCES (2024-2026)

1. Challenging the Slow-Correction Dogma (2025)

2. Urea Rehabilitation (2025)

3. Point-of-Care Ultrasound (PoCUS) for Volume Assessment (2026)

4. Vaptans in Heart Failure - Reassessment (2026)

5. HIT Trial - Targeted Sodium Correction

6. Proactive DDAVP "Clamp" Strategy

7. Satavaptan

Quick Reference Summary

• Rosen's Emergency Medicine, 10e - pp. 2520-2522 (types, signs, emergency management)
• Brenner & Rector's The Kidney, 11e - pp. 1901-1921 (cancer-related hyponatremia, SIADH)
• Goldman-Cecil Medicine, 27e - p. 838 (cirrhosis, tolvaptan)
• Henry's Clinical Diagnosis & Management by Laboratory Methods, 24e - pp. 133-135 (lab patterns)
• Ayus JC et al. Correction Rates and Clinical Outcomes in Severe Hyponatremia. JAMA Intern Med. 2025 (PMID 39556338)
• Chander S et al. Urea for SIADH-induced Hyponatremia. Am J Kidney Dis. 2025 (PMID 39362395)
• Del Castillo Tirado FJ et al. PoCUS in Hyponatremia. Intern Emerg Med. 2026 (PMID 41528666)
• Orman ES et al. AGA Practice Guideline: Hyponatremia in Cirrhosis. Gastroenterology. 2025 (PMID 41114681)
• Spasovski G. Hyponatremia - Treatment Standard 2024. Nephrol Dial Transplant. 2024